Want to see JP:2160 full AI Analyst Report?
Top Page
GNI Group
(2160)
Select Model
Select Model
Rating:51Neutral
Price Target:
¥3,653.00
▲(8.40% Upside)
Action:Reiterated
Date:09/19/26
The score is held back primarily by deteriorating financial performance, including renewed losses and ongoing cash burn, with valuation also constrained by negative earnings. These risks are partially offset by a strong technical uptrend, as the price is above key moving averages and momentum indicators remain positive.
Positive Factors
Strong Gross Margins
A roughly 75% TTM gross margin indicates the business retains substantial economics at the gross-profit level. If maintained, this cushion can help fund research, commercialization, and overhead while providing operating leverage when revenue growth improves, even though current net profitability is weak.
Negative Factors
Recurring Net Losses
The return to sizable operating and net losses after profits in 2023 and a small profit in 2024 shows that earnings conversion is highly volatile. Persistent losses can weaken retained capital, limit internally funded investment, and make sustainable profitability harder to establish over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Gross Margins
A roughly 75% TTM gross margin indicates the business retains substantial economics at the gross-profit level. If maintained, this cushion can help fund research, commercialization, and overhead while providing operating leverage when revenue growth improves, even though current net profitability is weak.
Read all positive factors
GNI Group (2160) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥210.68B
Dividend YieldN/A
Average Volume (3M)1.09M
Price to Earnings (P/E)―
Beta (1Y)1.27
Revenue Growth9.92%
EPS Growth-3255.60%
CountryJP
Employees990
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-102.58
Shares Outstanding65,850,494
10 Day Avg. Volume1,381,140
30 Day Avg. Volume1,091,396
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.52
Price to Sales (P/S)4.71
P/FCF Ratio-46.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)15.29
Revenue Forecast (FY)¥40.18B
GNI Group Business Overview & Revenue Model
Company Description
GNI Group Ltd. is a global biopharmaceutical enterprise dedicated to the research, development, manufacturing, and commercialization of both modern pharmaceuticals and traditional Chinese medicines. The company's lead product, Etuary, is currently...
GNI Group Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
66
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 26.52B | 26.84B | 23.61B | 26.01B | 17.42B | 12.69B |
| Gross Profit | 19.79B | 19.99B | 18.04B | 22.43B | 14.74B | 11.09B |
| EBITDA | -347.76M | -1.76B | 2.67B | 14.47B | 2.16B | 2.14B |
| Net Income | -5.49B | -4.41B | 1.10B | 8.09B | 388.83M | 1.07B |
Balance Sheet | ||||||
| Total Assets | 81.76B | 83.79B | 71.94B | 64.27B | 33.91B | 30.30B |
| Cash, Cash Equivalents and Short-Term Investments | 17.16B | 21.10B | 12.93B | 23.15B | 11.24B | 14.35B |
| Total Debt | 5.07B | 5.37B | 22.66B | 18.84B | 537.36M | 1.13B |
| Total Liabilities | 15.26B | 32.11B | 32.07B | 27.72B | 14.10B | 11.03B |
| Stockholders Equity | 40.44B | 50.15B | 36.45B | 33.79B | 20.97B | 18.86B |
Cash Flow | ||||||
| Free Cash Flow | -3.39B | -2.74B | -3.69B | 5.28B | -580.20M | 172.78M |
| Operating Cash Flow | -3.08B | -2.41B | -3.16B | 6.55B | 393.32M | 552.27M |
| Investing Cash Flow | -3.69B | 2.73B | -12.89B | -3.33B | -4.12B | 2.24B |
| Financing Cash Flow | 12.15B | 10.47B | 3.22B | 7.17B | -646.33M | 357.06M |
GNI Group Technical Analysis
Positive
3370.00
Price Trends
2916.76
Positive
2783.84
Positive
2823.47
Positive
Market Momentum
126.89
Positive
52.39
Neutral
30.95
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2160, the sentiment is Positive. The current price of 3370 is above the 20-day moving average (MA) of 3173.10, above the 50-day MA of 2916.76, and above the 200-day MA of 2823.47, indicating a bullish trend. The MACD of 126.89 indicates Positive momentum. The RSI at 52.39 is Neutral, neither overbought nor oversold. The STOCH value of 30.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2160.
GNI Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ¥114.10B | -14.13 | -12.23% | 0.33% | 7.12% | -137.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥210.68B | -29.98 | -11.51% | ― | 9.92% | -3255.60% | |
48 Neutral | ¥139.56B | -38.46 | -7.17% | ― | 0.62% | 27.66% | |
46 Neutral | ¥32.20B | -73.89 | ― | ― | 3.43% | -53.59% | |
43 Neutral | ¥79.54B | -21.71 | -37.79% | ― | ― | 5.71% |
* Healthcare Sector Average
JP:2160
GNI Group
3,075.00
694.00
29.15%
JP:4587
Peptidream
1,081.00
-465.50
-30.10%
JP:4592
SanBio Co
1,036.00
-2,599.00
-71.50%
JP:4565
Sosei Group
1,220.00
260.00
27.08%
JP:7774
Japan Tissue Engineering Co., Ltd.
801.00
315.00
64.81%
GNI Group Corporate Events
GNI Group to Join TOPIX as Global Biopharma Footprint Expands
Oct 7, 2026
GNI Group Ltd. has been selected for inclusion in the Tokyo Stock Price Index (TOPIX), with its shares scheduled to join the benchmark on October 30, 2026 under the first periodic review of the index reform. The move follows the company’s ex...
GNI Group Wins FDA Approval for First Proprietary Medtech Wound Matrix
Sep 3, 2026
GNI Group’s U.S.-based subsidiary Berkeley Advanced Biomaterials has secured FDA 510(k) clearance for Accelagen Plus Surgical Matrix, its first proprietary branded biomaterial product designed to support tissue formation and wound healing ac...
GNI Group Announces Change in Major Shareholder Following Blackstone-Linked Stake Sale
Aug 23, 2026
GNI Group Ltd. has reported a change in one of its major shareholders after receiving notice that BCP Asia AYM Holding (Cayman) L.P. reduced its stake to 6,541,304 shares through a partial sale on August 21, 2026. The shareholder is an exempted Ca...
GNI Group Maps Out ‘Second Founding Phase’ in Q2 FY2026 Results
Aug 18, 2026
GNI Group Ltd., listed on the Tokyo Stock Exchange under code 2160, is a pharmaceutical and life sciences company focusing on pain, rheumatism, and related therapeutic areas. It is growing through acquisitions, notably involving AYUMI Pharmaceutic...
GNI Group Lifts 2026 Revenue Outlook After AYUMI Deal, Holds Back Profit Guidance
Aug 14, 2026
GNI Group Ltd., a biopharmaceutical company listed on the TSE Growth market, develops therapies for liver disease and pain, anchored by its F351 liver fibrosis program. The recent consolidation of AYUMI Pharmaceutical strengthens its specialty pha...
GNI Group Narrows Losses in Q2 but Limits FY2026 Guidance to Revenue Amid Drug Investment Uncertainty
Aug 14, 2026
GNI Group reported Q2 FY2026 year-to-date revenue of ¥11,937 million, down 2.6% from a year earlier, while narrowing operating losses and posting a comprehensive income of ¥2,032 million despite a profit attributable to owners of the par...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.